Live to fight another day: Combining parenchymal sparing resection and ablative therapy in neuroendocrine tumor liver metastases

The past two decades have seen a dramatic increase in the treatment options for Neuroendocrine Tumor Liver Metastases (NETLM) with improving patient outcomes and expanding indications. For the management of this rare and heterogenous group of tumors to be informed by an extensive body of literature is a testament of the work and collaboration of high-volume centers across the globe, as well the value of international organizations such as the North American Neuroendocrine Tumor Society's (NANETS) and the European Neuroendocrine Tumor Society (ENETS). However, the level 1 evidence supporting choices in systemic management of NETLM is unmatched by the still relatively lacking evidence for their surgical management.